Appropriate number of plasma exchanges in Guillain‐Barré syndrome
- 1 March 1997
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 41 (3) , 298-306
- https://doi.org/10.1002/ana.410410304
Abstract
Plasma exchange (PE) is the standard treatment in Guillain‐Barré syndrome (GBS) patients who have lost the ability to walk. The effect of exchanges before this stage and the optimal number of exchanges for the other patients are still unknown. We randomized 556 GBS patients according to severity and number of exchanges as follows: Zero versus 2 PEs for patients who could walk—with or without aid—but not run, or who could stand up unaided (mild group); 2 versus 4 PEs for patients who could not stand up unaided (moderate group); and 4 versus 6 PEs for mechanically ventilated patients (severe group). In the mild group, 2 PEs were more effective than none for time to onset of motor recovery (median, 4 vs 8 days, respectively). In the moderate group, 4 PEs were more beneficial than 2 for time to walk with assistance (median, 20 vs 24 days) and for 1‐year full muscle‐strength recovery rate (64% vs 46%). Six PEs were no more beneficial than 4 in the severe cases. Patients with mild GBS on admission should receive 2 PEs. Patients with moderate and severe forms should benefit from 2 further exchanges.Keywords
This publication has 19 references indexed in Scilit:
- Plasma exchange and intravenous immunoglobulin treatment of neuromuscular diseaseAnnals of Neurology, 1994
- Plasma exchange in Guillain‐Barré syndrome: One‐year follow‐upAnnals of Neurology, 1992
- A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Plasmapheresis and guillain‐barré syndrome: Analysis of prognostic factors and the effect of plasmapheresisAnnals of Neurology, 1988
- EARLY RELAPSES AFTER PLASMA EXCHANGE IN ACUTE INFLAMMATORY POLYRADICULONEUROPATHYThe Lancet, 1986
- The Utility of Therapeutic Plasmapheresis for Neurological DisordersPublished by American Medical Association (AMA) ,1986
- PROGNOSIS IN GUILLAIN-BARRÉSYNDROMEThe Lancet, 1985
- In vivo demyelinating activity of sera from patients with Guillain‐Barré syndromeAnnals of Neurology, 1982
- CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHYThe Lancet, 1978
- Circulating Demyelinating Factors in Acute Idiopathic PolyneuropathyArchives of Neurology, 1971